Evidence map›Paper›PMID 40584226›Full record

ArticleCancer management and research2025

Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients.

Xin Gao, Yijun Fu, Zimei Mo, Yongtong Ruan

Abstract read
In one paragraph

Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xin Gao *Department of Urology, Yangjiang Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Yangjiang, Guangdong, People's Republic of China.ORCID 0009-0002-1771-7668
Yijun Fu *Department of Urology, Yangjiang Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Yangjiang, Guangdong, People's Republic of China.ORCID 0009-0002-8963-8002
Zimei MoDepartment of Urology, Yangjiang Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Yangjiang, Guangdong, People's Republic of China.ORCID 0009-0000-0926-5177
Yongtong RuanDepartment of Urology, Yangjiang Hospital of Traditional Chinese Medicine, Yangjiang, Guangdong, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer remains a significant global health burden, with biochemical recurrence (BCR) affecting 20-50% of patients post-radical prostatectomy. This study aimed to investigate the relationship between preoperative PSA levels and BCR-free survival in Asian populations. Methods: We conducted a retrospective cohort study of 3,092 prostate cancer patients who underwent radical prostatectomy at Yonsei University College of Medicine, Korea (1992-2014). The exposure variable was preoperative PSA level, and the primary outcome was BCR-free survival. Covariates included age, Gleason score, pathological stage, surgical margins, and other clinical factors. Patients were followed quarterly for two years post-surgery, semi-annually for three years, then annually thereafter (median follow-up: 66 months). Results: Using piecewise linear regression, we identified a significant threshold effect at PSA 5.1 ng/mL. Above this threshold, each unit increase in LnPSA was associated with a 6.10-month reduction in BCR-free survival (95% CI: -7.64 to -4.56, P<0.0001). Higher PSA levels correlated with increased adverse pathological features and shorter BCR-free survival across all risk groups. Conclusion: This study establishes a critical PSA threshold of 5.1 ng/mL for BCR risk stratification in Asian populations. Above this threshold, each unit increase in LnPSA correlates with a 6.10-month reduction in BCR-free survival, providing valuable guidance for post-operative monitoring and personalized treatment strategies.

Indexed as

biochemical recurrencenonlinearityprostate cancerprostate-specific antigenPSA

Identifiers

PMID40584226
PMCPMC12205703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.